千金药业：关于子公司获得药品注册证书的公告

Core Viewpoint - Qianjin Pharmaceutical announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of aluminum magnesium carbonate chewable tablets, indicating successful consistency evaluation for treating upper gastrointestinal diseases such as gastritis and ulcers [1] Group 1 - The approved product is aluminum magnesium carbonate chewable tablets with a specification of 0.5g [1] - The expected domestic sales for 2024 are projected to be 990 million yuan [1] - The total research and development investment for the product amounts to 1.0047 million yuan [1]